RHODE ISLAND HOSPITAL
- Type
- Teaching hospital
- Where
- Newport, RI
- Medicare CCN
- 410007
- Received
- $7,677,477 in 542 records, 2019 ($263,708 general, $7,413,769 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: RHODE ISLAND HOSPITAL Fuzzy (name and state)
- Federal award recipient: RHODE ISLAND HOSPITAL Fuzzy (name and state)
- Nonprofit: RHODE ISLAND HOSPITAL Fuzzy (name and state)
- Patent assignee: Rhode Island Hospital Fuzzy (name and state)
- Trademark owner: Rhode Island Hospital Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 38 | $263,708 |
| 2019 | Research payment | 504 | $7,413,769 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 504 | $7,413,769 |
| Grant | 14 | $193,432 |
| Education | 2 | $27,262 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 3 | $13,613 |
| Space rental or facility fees (teaching hospital only) | 7 | $12,330 |
| Gift | 7 | $8,939 |
| Charitable Contribution | 1 | $3,500 |
| Honoraria | 1 | $2,400 |
| Consulting Fee | 1 | $2,145 |
| Royalty or License | 2 | $84 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | BioFire Diagnostics, LLC | $22,500 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-12-31 | ABBVIE INC. | $15,384 | Research payment | Cash or cash equivalent | M16-573 | 2019 | |
| 2019-12-31 | Medartis Inc. | $4,430 | Gift | In-kind items and services | APTUS Device, ORTHO | 2019 | |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $1,653 | Research payment | In-kind items and services | A Phase 1, Open-label, Dose-escalation and Expansion Study of MEDI1191 Administered Intratumorally as Monotherapy and in | 2019 | |
| 2019-12-31 | AstraZeneca UK Limited | $1,002 | Research payment | In-kind items and services | This is an open label non randomised study designed to provide continued access to AZD1775 for eligible patients with ad | 2019 | |
| 2019-12-31 | Linvatec Corporation | $280 | Grant | In-kind items and services | HALL POWER Device, ORTHOPEDIC SURGERY | 2019 | |
| 2019-12-31 | Abbott Laboratories | $70 | Research payment | In-kind items and services | Heart Failure Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) | 2019 |
| 2019-12-30 | Chugai Pharmaceutical Co., Ltd. | $1,500 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, An Anti-Glypican3 GPC3CD3 Bispecific Antibody, in Patien | 2019 |
| 2019-12-30 | Chugai Pharmaceutical Co., Ltd. | $1,300 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, An Anti-Glypican3 GPC3CD3 Bispecific Antibody, in Patien | 2019 |
| 2019-12-27 | PFIZER INC. | $3,000 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-12-24 | Boston Scientific Corporation | $8,117 | Research payment | Cash or cash equivalent | GENERAL PAIN MANAGEMENT Device, PAIN MANAGEMENT | Objective Markers of Pain during SCS | 2019 |
| 2019-12-23 | ABBVIE INC. | $6,282 | Research payment | Cash or cash equivalent | M15-570 | 2019 | |
| 2019-12-19 | Abbott Laboratories | $6,500 | Research payment | Cash or cash equivalent | Heart Failure Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) | 2019 |
| 2019-12-17 | Medical Device Business Services, Inc. | $7,330 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | MATRIX Device, Spine | 2019 | |
| 2019-12-17 | EMD Serono, Inc. | $1,491 | Research payment | Cash or cash equivalent | Bavencio Biological, Oncology | MS100070-0176 | 2019 |
| 2019-12-16 | BioFire Diagnostics, LLC | $7,422 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-12-16 | ABBVIE INC. | $3,000 | Research payment | Cash or cash equivalent | M15-913 | 2019 | |
| 2019-12-16 | AKEBIA THERAPEUTICS INC | $674 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-12-12 | Masimo Corporation | $6,907 | Research payment | Cash or cash equivalent | rainbow Acoustic Monitoring Device, Devices | Suner Rhode Island Hospital NIBp | 2019 |
| 2019-12-12 | Abbott Laboratories | $3,500 | Research payment | Cash or cash equivalent | Heart Failure Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) | 2019 |
| 2019-12-11 | EMD Serono, Inc. | $3,555 | Research payment | Cash or cash equivalent | Bavencio Biological, Oncology | EMR 100070-001 | 2019 |
| 2019-12-09 | BioFire Diagnostics, LLC | $63 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-12-06 | Adaptive Biotechnologies Corporation | $90,900 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | 297381-29 | 2019 |
| 2019-12-06 | Genentech, Inc. | $3,500 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER | 2019 |
| 2019-12-06 | PFIZER INC. | $2,900 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-12-05 | SANOFI PASTEUR INC. | $19,942 | Research payment | Cash or cash equivalent | NO PRODUCT DISCUSSED Drug | 2019 | |
| 2019-12-05 | Actelion Pharmaceuticals US, Inc. | $8,700 | Research payment | Cash or cash equivalent | SPHERE - AC-065A402 | 2019 | |
| 2019-12-05 | PFIZER INC. | $4,900 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY O | 2019 | |
| 2019-12-05 | EMD Serono, Inc. | $2,720 | Research payment | Cash or cash equivalent | Bavencio Biological, Oncology | MS100070-0176 | 2019 |
| 2019-12-05 | CSL Behring | $1,403 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-12-05 | PFIZER INC. | $572 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY O | 2019 | |
| 2019-12-05 | PFIZER INC. | $166 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY O | 2019 | |
| 2019-12-04 | AKEBIA THERAPEUTICS INC | $823 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-12-04 | AKEBIA THERAPEUTICS INC | $760 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-12-04 | AKEBIA THERAPEUTICS INC | $674 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-12-03 | Incyte Corporation | $1,603 | Research payment | Cash or cash equivalent | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | 2019 | |
| 2019-12-03 | AKEBIA THERAPEUTICS INC | $853 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-12-03 | AKEBIA THERAPEUTICS INC | $823 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-12-03 | AKEBIA THERAPEUTICS INC | $810 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-12-02 | Roche Products Limited | $8,471 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OCRELIZUMAB IN PPMS | 2019 |
| 2019-11-27 | ABBVIE INC. | $29,117 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-11-27 | ABBVIE INC. | $2,102 | Research payment | Cash or cash equivalent | M15-913 | 2019 | |
| 2019-11-27 | ABBVIE INC. | $1,409 | Research payment | Cash or cash equivalent | M16-573 | 2019 | |
| 2019-11-26 | Amgen Inc. | $83 | Research payment | In-kind items and services | Otezla Biological, Inflammation | Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis. FOREMOST | 2019 |
| 2019-11-25 | BioFire Diagnostics, LLC | $32 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-11-22 | Merck Sharp & Dohme LLC | $5,509 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as | 2019 |
| 2019-11-22 | Daiichi Sankyo Inc. | $5,500 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176b-D-U312 Pediatric | 2019 |
| 2019-11-22 | Merck Sharp & Dohme LLC | $4,245 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as | 2019 |
| 2019-11-22 | Cook Research Incorporated | $2,540 | Research payment | Cash or cash equivalent | 2019 | ||
| 2019-11-22 | Genentech, Inc. | $939 | Research payment | Cash or cash equivalent | Zelboraf Biological, BioOncology | PHASE III BRAF MEK COMBINATION | 2019 |
| 2019-11-21 | Cardiovascular Systems Inc. | $75 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-11-20 | Merck Sharp & Dohme LLC | $132,942 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Multicenter, Randomized Phase II study evaluating Pembrolizumab in combination with chemotherapy and chemoradiation in l | 2019 |
| 2019-11-20 | GE HEALTHCARE | $3,500 | Charitable Contribution | Cash or cash equivalent | Device, DETECTION & GUIDANCE SOLUTIONS | 2019 | |
| 2019-11-19 | Takeda Pharmaceuticals U.S.A., Inc. | $7,231 | Research payment | Cash or cash equivalent | NINLARO Drug, Oncology | Ixazomib, Oral Metronomic Cyclophosphamide and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Br | 2019 |
| 2019-11-18 | Gilead Sciences, Inc. | $14,350 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and S | 2019 | |
| 2019-11-18 | AKEBIA THERAPEUTICS INC | $189 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-18 | AKEBIA THERAPEUTICS INC | $152 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-18 | AKEBIA THERAPEUTICS INC | $152 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-18 | AKEBIA THERAPEUTICS INC | $126 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-12 | BioFire Diagnostics, LLC | $6,971 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-11-12 | AKEBIA THERAPEUTICS INC | $731 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-12 | AKEBIA THERAPEUTICS INC | $674 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-07 | Regeneron Pharmaceuticals, Inc. | $34,298 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 PD 1, | 2019 |
| 2019-11-07 | Regeneron Pharmaceuticals, Inc. | $14,259 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 PD 1, | 2019 |
| 2019-11-07 | Regeneron Pharmaceuticals, Inc. | $1,839 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 PD 1, | 2019 |
| 2019-11-07 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY O | 2019 | |
| 2019-11-07 | CSL Behring | $50 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-11-07 | BioFire Diagnostics, LLC | $40 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-11-06 | SANOFI PASTEUR INC. | $93,063 | Research payment | Cash or cash equivalent | NO PRODUCT DISCUSSED Drug | 2019 | |
| 2019-11-06 | KLS-Martin L.P. | $10,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-11-05 | ABBVIE INC. | $1,824 | Research payment | Cash or cash equivalent | M16-573 | 2019 | |
| 2019-11-05 | Incyte Corporation | $1,450 | Research payment | Cash or cash equivalent | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | 2019 | |
| 2019-11-04 | Genentech, Inc. | $5,256 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | APDL1 A PHASE II OPEN LABEL RANDOMIZED IN PATS WITH NSCLC | 2019 |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $1,190 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $790 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $790 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $760 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $760 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $674 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-11-04 | Alexion Pharmaceuticals, Inc. | $400 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia HPP | 2019 |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $394 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-11-04 | Alexion Pharmaceuticals, Inc. | $320 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia HPP | 2019 |
| 2019-11-01 | ABBVIE INC. | $17,365 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-11-01 | AKEBIA THERAPEUTICS INC | $5,600 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-11-01 | AKEBIA THERAPEUTICS INC | $5,600 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-11-01 | EMD Serono, Inc. | $3,132 | Research payment | Cash or cash equivalent | Bavencio Biological, Oncology | EMR 100070-007 | 2019 |
| 2019-11-01 | Abbott Laboratories | $2,625 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | DAPT study | 2019 |
| 2019-11-01 | AKEBIA THERAPEUTICS INC | $1,000 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-11-01 | AKEBIA THERAPEUTICS INC | $1,000 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-10-31 | BioFire Diagnostics, LLC | $9,526 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-10-31 | BioFire Diagnostics, LLC | $7,500 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-10-31 | PFIZER INC. | $1,800 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-10-30 | ABBVIE INC. | $4,946 | Research payment | Cash or cash equivalent | M15-913 | 2019 | |
| 2019-10-30 | Cardiovascular Systems Inc. | $1,872 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-10-30 | ABBVIE INC. | $1,288 | Research payment | Cash or cash equivalent | M15-570 | 2019 | |
| 2019-10-30 | Cardiovascular Systems Inc. | $43 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-10-28 | BioFire Diagnostics, LLC | $12,968 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-10-28 | BioFire Diagnostics, LLC | $12,707 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-10-28 | BioFire Diagnostics, LLC | $9,372 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-10-28 | BioFire Diagnostics, LLC | $8,335 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-10-28 | BioFire Diagnostics, LLC | $2,644 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-10-25 | Merck Sharp & Dohme LLC | $2,657 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as | 2019 |
| 2019-10-24 | Biogen, Inc. | $11,945 | Research payment | Cash or cash equivalent | A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion | 2019 | |
| 2019-10-24 | F. Hoffmann-La Roche AG | $2,535 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2019 |
| 2019-10-23 | Merck Sharp & Dohme LLC | $10,722 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as | 2019 |
| 2019-10-22 | Genentech, Inc. | $12,800 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH1B 2 TDB CHP POLA IN NHL FOR DOSE ESCALATION PH1B FOLLOWED BY 1L DLBCL FOR EXPANSION PH2 | 2019 |
| 2019-10-22 | AKEBIA THERAPEUTICS INC | $917 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-10-22 | AKEBIA THERAPEUTICS INC | $917 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-10-21 | SEAGEN INC. | $3,152 | Research payment | Cash or cash equivalent | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2019 | |
| 2019-10-15 | EMD Serono, Inc. | $13,500 | Research payment | Cash or cash equivalent | Bavencio Biological, Oncology | MS100070-0176 | 2019 |
| 2019-10-15 | ABBVIE INC. | $1,616 | Research payment | Cash or cash equivalent | Rinvoq Biological, Immunology | M16-047 | 2019 |
| 2019-10-14 | E.R. Squibb & Sons, L.L.C. | $10,500 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Backgro | 2019 | |
| 2019-10-14 | Bayer Healthcare Pharmaceuticals Inc. | $8,700 | Research payment | Cash or cash equivalent | Non-Covered | Combo with PD-1 inhibitor | 2019 |
| 2019-10-10 | Bayer Healthcare Pharmaceuticals Inc. | $800 | Research payment | Cash or cash equivalent | Non-Covered | Combo with PD-1 inhibitor | 2019 |
| 2019-10-09 | Olympus America Inc. | $3,543 | Gift | In-kind items and services | Olympus Capital Accessories Device, Surgical Endoscopy Products | 2019 | |
| 2019-10-08 | Davol Inc. | $2,145 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-10-08 | Genentech, Inc. | $340 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC | 2019 |
| 2019-10-07 | SANOFI PASTEUR INC. | $14,956 | Research payment | Cash or cash equivalent | NO PRODUCT DISCUSSED Drug | 2019 | |
| 2019-10-04 | Abbott Laboratories | $439 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-10-04 | Abbott Laboratories | $313 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-10-03 | Ipsen Biopharmaceuticals, Inc | $49,431 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | BrUOG 329 Onivyde Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma APhase I | 2019 |
| 2019-10-02 | ABBVIE INC. | $25,119 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-10-02 | Genentech, Inc. | $9,000 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER | 2019 |
| 2019-10-02 | ABBVIE INC. | $5,967 | Research payment | Cash or cash equivalent | M16-438 | 2019 | |
| 2019-10-02 | ABBVIE INC. | $1,135 | Research payment | Cash or cash equivalent | M16-573 | 2019 | |
| 2019-10-02 | AKEBIA THERAPEUTICS INC | $760 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-10-02 | AKEBIA THERAPEUTICS INC | $760 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-10-02 | Cardiovascular Systems Inc. | $56 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-10-01 | GenMark Diagnostics, Inc. | $2,400 | Honoraria | Cash or cash equivalent | 2019 | ||
| 2019-10-01 | AKEBIA THERAPEUTICS INC | $790 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-10-01 | AKEBIA THERAPEUTICS INC | $760 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-10-01 | AKEBIA THERAPEUTICS INC | $760 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-10-01 | AKEBIA THERAPEUTICS INC | $760 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-10-01 | AKEBIA THERAPEUTICS INC | $674 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-10-01 | AKEBIA THERAPEUTICS INC | $674 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-10-01 | AKEBIA THERAPEUTICS INC | $674 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-10-01 | AKEBIA THERAPEUTICS INC | $674 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-10-01 | AKEBIA THERAPEUTICS INC | $674 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-10-01 | AKEBIA THERAPEUTICS INC | $674 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-10-01 | AKEBIA THERAPEUTICS INC | $674 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-09-30 | BioFire Diagnostics, LLC | $15,000 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-09-30 | ABBVIE INC. | $4,707 | Research payment | Cash or cash equivalent | M15-913 | 2019 | |
| 2019-09-30 | PFIZER INC. | $1,200 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-09-27 | ABBVIE INC. | $1,288 | Research payment | Cash or cash equivalent | M15-570 | 2019 | |
| 2019-09-25 | AstraZeneca Pharmaceuticals LP | $29,636 | Research payment | Cash or cash equivalent | A Phase 1, Open-label, Dose-escalation and Expansion Study of MEDI1191 Administered Intratumorally as Monotherapy and in | 2019 | |
| 2019-09-24 | Incyte Corporation | $10,000 | Research payment | Cash or cash equivalent | TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | 2019 | |
| 2019-09-24 | Cook Research Incorporated | $9,790 | Research payment | Cash or cash equivalent | 2019 | ||
| 2019-09-19 | Merck Sharp & Dohme LLC | $485 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously U | 2019 |
| 2019-09-17 | CSL Behring | $50 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-09-16 | Bio-Rad Laboratories, Inc. | $18 | Gift | Cash or cash equivalent | Electrophoresis Reagents Device, Electrophoresis | 2019 | |
| 2019-09-13 | Masimo Corporation | $250 | Research payment | In-kind items and services | EMMA and ISA Device, Devices | Suner Rhode Island Hospital NIBp | 2019 |
| 2019-09-13 | Masimo Corporation | $250 | Research payment | In-kind items and services | Patient SafetyNet System Device, Devices | Suner Rhode Island Hospital NIBp | 2019 |
| 2019-09-13 | Masimo Corporation | $45 | Research payment | In-kind items and services | EMMA and ISA Device, Devices | Suner Rhode Island Hospital NIBp | 2019 |
| 2019-09-13 | Masimo Corporation | $22 | Research payment | In-kind items and services | rainbow Acoustic Monitoring Device, Devices | Suner Rhode Island Hospital NIBp | 2019 |
| 2019-09-13 | Masimo Corporation | $22 | Research payment | In-kind items and services | EMMA and ISA Device, Devices | Suner Rhode Island Hospital NIBp | 2019 |
| 2019-09-12 | ABBVIE INC. | $16,966 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-09-12 | Celgene Corporation | $10,576 | Research payment | Cash or cash equivalent | CC-486 Drug | (AZA-JMML-001) PhII Azacitidine Open-label PK, Pharmacodynamics, Safety, Activity vs Historical Controls in Peds With ND | 2019 |
| 2019-09-12 | Cook Research Incorporated | $1,415 | Research payment | Cash or cash equivalent | Cook Medical Filters Device, Peripheral Intervention | IVC Filter Study | 2019 |
| 2019-09-12 | ABBVIE INC. | $243 | Research payment | Cash or cash equivalent | M15-913 | 2019 | |
| 2019-09-12 | Cook Research Incorporated | $99 | Research payment | Cash or cash equivalent | Cook Medical Filters Device, Peripheral Intervention | IVC Filter Study | 2019 |
| 2019-09-10 | Incyte Corporation | $60 | Research payment | Cash or cash equivalent | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | 2019 | |
| 2019-09-09 | PFIZER INC. | $5,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-09-05 | AKEBIA THERAPEUTICS INC | $760 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-09-05 | AKEBIA THERAPEUTICS INC | $760 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-09-05 | AKEBIA THERAPEUTICS INC | $760 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-09-05 | AKEBIA THERAPEUTICS INC | $680 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-09-05 | AKEBIA THERAPEUTICS INC | $680 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2019 | |
| 2019-09-05 | Cardiovascular Systems Inc. | $75 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-09-04 | Incyte Corporation | $3,054 | Research payment | Cash or cash equivalent | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | 2019 | |
| 2019-09-04 | BioFire Diagnostics, LLC | $18 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-09-02 | Genentech, Inc. | $1,500 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER | 2019 |
| 2019-08-30 | ABBVIE INC. | $2,486 | Research payment | Cash or cash equivalent | Humira Biological, Immunology | M15-574 | 2019 |
| 2019-08-29 | ABBVIE INC. | $18,057 | Research payment | Cash or cash equivalent | M16-573 | 2019 | |
| 2019-08-29 | Linvatec Corporation | $15,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-08-29 | ABBVIE INC. | $11,694 | Research payment | Cash or cash equivalent | M16-438 | 2019 | |
| 2019-08-29 | ABBVIE INC. | $1,677 | Research payment | Cash or cash equivalent | M15-570 | 2019 | |
| 2019-08-29 | Cochlear Americas | $246 | Grant | In-kind items and services | Nucleus Device, Implantable hearing solution | 2019 | |
| 2019-08-29 | BioFire Diagnostics, LLC | $130 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-08-27 | Incyte Corporation | $1,000 | Research payment | Cash or cash equivalent | TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | 2019 | |
| 2019-08-26 | Takeda Pharmaceuticals U.S.A., Inc. | $28,991 | Research payment | Cash or cash equivalent | NINLARO Drug, Oncology | Ixazomib, Oral Metronomic Cyclophosphamide and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Br | 2019 |
| 2019-08-26 | BioFire Diagnostics, LLC | $4,650 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-08-26 | Genentech, Inc. | $3,000 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE I PROTOCOL COMBO FOR MULTIPLE MYELOMA WITH LENALIDOMIDE | 2019 |
| 2019-08-26 | PFIZER INC. | $2,200 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-08-26 | Genentech, Inc. | $510 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE I PROTOCOL COMBO FOR MULTIPLE MYELOMA WITH LENALIDOMIDE | 2019 |
| 2019-08-22 | Merck Sharp & Dohme LLC | $10,826 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as | 2019 |
| 2019-08-15 | Orthofix Medical, Inc. | $13,902 | Research payment | Cash or cash equivalent | Physio-Stim Osteogenesis Stimulator Device, STIMULATOR, BONE GROWTH, NON-INVASIVE | PSOA | 2019 |
| 2019-08-15 | Genentech, Inc. | $2,600 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE I PROTOCOL COMBO FOR MULTIPLE MYELOMA WITH LENALIDOMIDE | 2019 |
| 2019-08-14 | AKEBIA THERAPEUTICS INC | $950 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-08-14 | Abbott Laboratories | $637 | Research payment | Cash or cash equivalent | Axium and Proclaim Neurostimulator Systems Device, Cardiac Arrhythmias and Heart Failure | TARGET: A Post-Approval Study to Evaluate Targeted SCS (DRG) Stimulation for the management of Moderate to Severe Chroni | 2019 |
| 2019-08-13 | Genentech, Inc. | $12,800 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH2 | 2019 |
| 2019-08-13 | CSL Behring | $9,578 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-08-13 | Incyte Corporation | $3,500 | Research payment | Cash or cash equivalent | TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | 2019 | |
| 2019-08-13 | CSL Behring | $400 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-08-09 | Masimo Corporation | $5,407 | Research payment | Cash or cash equivalent | EMMA and ISA Device, Devices | Suner Rhode Island Hospital NIBp | 2019 |
| 2019-08-08 | Incyte Corporation | $38 | Research payment | Cash or cash equivalent | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | 2019 | |
| 2019-08-08 | Incyte Corporation | $23 | Research payment | Cash or cash equivalent | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | 2019 | |
| 2019-08-08 | Incyte Corporation | $23 | Research payment | Cash or cash equivalent | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | 2019 | |
| 2019-08-07 | BioFire Diagnostics, LLC | $215 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-08-05 | BioFire Diagnostics, LLC | $9,300 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-08-03 | PFIZER INC. | $5,000 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 | 2019 |
The latest 200 records of 542.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Newport, RI, county Newport County, RI, state Rhode Island; placed by its city name.
| Measure | Place (city or town) Newport, RI | County Newport County, RI | State Rhode Island |
|---|---|---|---|
| Population B01003 | 24,874 | 84,657 | 1,101,801 |
| Population, 2020 census P1 | 25,163 | 85,643 | 1,097,379 |
| Median age B01002 | 37.2 | 46.9 | 40.6 |
| Under 18 B01001 | 13.4% | 16.0% | 18.8% |
| 65 and over B01001 | 22.2% | 25.5% | 18.7% |
| Households B11001 | 11,049 | 36,868 | 441,570 |
| Foreign born B05002 | 7.4% | 7.0% | 15.3% |
| Median household income B19013 | $86,313 | $103,514 | $87,796 |
| Median family income B19113 | $118,598 | $135,124 | $112,375 |
| Per capita income B19301 | $58,057 | $61,596 | $47,150 |
| Poverty rate B17001 | 16.5% | 8.5% | 11.2% |
| Unemployment rate B23025 | 9.0% | 5.8% | 5.8% |
| Civilian labor force B23025 | 12,474 | 44,020 | 594,253 |
| Mean commute (minutes) B08013 | 18.9 | 22.8 | 25.5 |
| Bachelor's degree or higher B15003 | 57.9% | 54.1% | 37.7% |
| Housing units B25001 | 13,552 | 43,663 | 485,932 |
| Owner-occupied B25003 | 49.8% | 67.9% | 63.6% |
| Renters B25003 | 50.2% | 32.1% | 36.4% |
| Median home value B25077 | $746,900 | $609,700 | $404,200 |
| Median gross rent B25064 | $1,698 | $1,713 | $1,342 |
| White, not Hispanic B03002 | 74.1% | 82.4% | 68.0% |
| Black B03002 | 5.9% | 3.2% | 4.9% |
| Hispanic or Latino B03002 | 10.5% | 6.7% | 17.7% |
| Asian B03002 | 2.7% | 1.7% | 3.5% |
| American Indian and Alaska Native B03002 | 0.5% | 0.2% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Newport, RI.
Comments